Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 1.00 |
| ▸ | KIT | P10721 | 11/20 | 1.00 |
| ▸ | LDLR | P01130 | 8/20 | 1.00 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | LCK | P06239 | 4/20 | 1.00 |
| ▸ | LYN | P07948 | 4/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 4/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL29580067 | 1.00 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL7901 | 1.00 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28569394 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1984397 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL434496 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL9990634 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL31005052 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL26181009 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629369-B2 | Pharmaceutical compositions of nilotinib | AZURITY PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20250375449-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | XSPRAY PHARMA AB (SE) | 2025-12-11 | — | — | US | claimed |
| US-20250332165-A1 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-30 | — | — | US | claimed |
| US-12419892-B2 | Pharmaceutical compositions comprising nilotinib | XSPRAY PHARMA AB (SE) | 2025-09-23 | — | — | US | claimed |
| CN-116102540-B | Novel two nilotinib free base crystal forms and preparation method thereof | 浙江工业大学 | 2025-03-25 | — | — | CN | claimed |
| US-20250032491-A1 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | FLEX PHARMA, LLC | 2025-01-30 | — | — | US | claimed |
| US-12186316-B2 | Pharmaceutical compositions | Shenzhen Pharmacin Co., Ltd. (CN) | 2025-01-07 | — | — | US | claimed |
| CN-118580222-A | Nilotinib-flavonoid drug co-crystal and preparation method thereof | 浙江工业大学 | 2024-09-03 | — | — | CN | claimed |
| US-12053471-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2024-08-06 | — | — | US | claimed |
| US-20230075170-A1 | NOVEL SALTS OF NILOTINIB AND POLYMORPHIC FORMS THEREOF | CIPLA LIMITED (IN) | 2023-03-09 | — | — | US | claimed |
| EP-4142699-A1 | ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB | Nanocopoeia LLC (US) | 2023-03-08 | — | — | EP | claimed |
| US-11559485-B2 | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib | NANOCOPOEIA, LLC (US) | 2023-01-24 | — | — | US | claimed |
| CN-115569137-A | Salts of kinase inhibitors and compositions thereof | 汉达癌症医药责任有限公司 | 2023-01-06 | — | — | CN | claimed |
| US-20220378788-A1 | ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB AND IN VITRO CHARACTERIZATION THEREOF | FLEX PHARMA, LLC | 2022-12-01 | — | — | US | claimed |
| WO-2022182292-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-01 | — | — | WO | claimed |
| CN-114853734-A | Preparation method of nilotinib free base | 海南鑫开源医药科技有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-11389450-B2 | Amorphous nilotinib microparticles and uses thereof | NANOCOPOEIA, LLC (US) | 2022-07-19 | — | — | US | claimed |
| WO-2022068876-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-04-07 | — | — | WO | claimed |
| CN-112294971-B | Nilotinib compositions having improved solubility | 深圳市泰力生物医药有限公司 | 2022-02-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629369-B2 | Pharmaceutical compositions of nilotinib | CSNK1D, PPARD, TP53 | ABL1 23/4885BCR 962/4885KIT 171/4885 |
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | ABL1, FLT3, BCR | ABL1 1/4885BCR 3/4885KIT 56/4885 |
| US-20250032491-A1 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-12053471-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-20220378788-A1 | ORALLY DISINTEGRATING TABLET COMPRISING AMORPHOUS SOLID DISPERSION OF NILOTINIB AND IN VITRO CHARACTERIZATION THEREOF | ABL1, CDK2, CDKN1A | ABL1 1/4885BCR 164/4885KIT 188/4885 |
| US-11389450-B2 | Amorphous nilotinib microparticles and uses thereof | ABL1, CDKN1A, CDK2 | ABL1 1/4885BCR 173/4885KIT 246/4885 |
| US-12186316-B2 | Pharmaceutical compositions | ABL1, ABCG2, LIPA | ABL1 1/4885BCR 89/4885KIT 247/4885 |
| US-20230075170-A1 | NOVEL SALTS OF NILOTINIB AND POLYMORPHIC FORMS THEREOF | ABL1, TP53, MDH1 | ABL1 1/4885BCR 155/4885KIT 2034/4885 |
| US-11559485-B2 | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib | ABL1, CDK2, CDKN1A | ABL1 1/4885BCR 270/4885KIT 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.